Evidence map›Paper›PMID 37692259›Full record

ArticleTherapeutic advances in neurological disorders2023

Factors associated with depressive mood at the onset of multiple sclerosis - an analysis of 781 patients of the German NationMS cohort.

Anke Salmen, Robert Hoepner, Vinzenz Fleischer, Milena Heldt, Barbara Gisevius, Jeremias Motte, Klemens Ruprecht, Ruth Schneider, Anna Lena Fisse, Thomas Grüter and 25 more

Open access · goldAbstract read
In one paragraph

Article in Therapeutic advances in neurological disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Depression and anxiety in multiple sclerosis. Review of a fatal combination.Journal of neural transmission (Vienna, Austria : 1996) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 17 institutions in 2 countries.

Anke SalmenDepartment of Neurology, St. Josef-Hospital Bochum, Ruhr-University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany.ORCID https://orcid.org/0000-0002-4751-299X
Robert HoepnerDepartment of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.ORCID https://orcid.org/0000-0002-0115-7021
Vinzenz FleischerDepartment of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.ORCID https://orcid.org/0000-0002-3293-5121
Milena HeldtDepartment of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Barbara GiseviusDepartment of Neurology, St. Josef-Hospital Bochum, Ruhr-University Bochum, Bochum, Germany.
Jeremias MotteDepartment of Neurology, St. Josef-Hospital Bochum, Ruhr-University Bochum, Bochum, Germany.ORCID https://orcid.org/0000-0002-6624-8565
Klemens RuprechtDepartment of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Ruth SchneiderDepartment of Neurology, St. Josef-Hospital Bochum, Ruhr-University Bochum, Bochum, Germany.
Anna Lena FisseDepartment of Neurology, St. Josef-Hospital Bochum, Ruhr-University Bochum, Bochum, Germany.ORCID https://orcid.org/0000-0003-0493-8656
Thomas GrüterDepartment of Neurology, St. Josef-Hospital Bochum, Ruhr-University Bochum, Bochum, Germany.
Carsten LukasDepartment of Neurology, St. Josef-Hospital Bochum, Ruhr-University Bochum, Bochum, Germany.
Achim BertheleDepartment of Neurology, Klinikum rechtsDer Isar, Technical University of Munich, Munich, Germany.
Katrin GiglhuberDepartment of Neurology, Klinikum rechtsDer Isar, Technical University of Munich, Munich, Germany.
Martina FlaskampDepartment of Neurology, Klinikum rechtsDer Isar, Technical University of Munich, Munich, Germany.
Mark MühlauDepartment of Neurology, Klinikum rechtsDer Isar, Technical University of Munich, Munich, Germany.
Jan KirschkeDepartment of Neuroradiology, Klinikum rechtsDer Isar, Technical University of Munich, Munich, Germany.
Stefan BittnerDepartment of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Sergiu GroppaDepartment of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Felix LüssiDepartment of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.ORCID https://orcid.org/0000-0003-4334-4199
Antonios BayasDepartment of Neurology, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
Sven MeuthDepartment of Neurology, Medical Faculty, Heinrich-Heine University Düsseldorf, Germany.
Cristoph HeesenDepartment of Neurology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.ORCID https://orcid.org/0000-0001-8131-9467
Corinna TrebstDepartment of Neurology, Hannover Medical School, Hannover, Germany.
Brigitte WildemannMolecular Neuroimmunology Group, Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany.
Florian Then BerghDepartment of Neurology, University of Leipzig, Leipzig, Germany.
Gisela AntonyCentral Information Office German Competence Network of Multiple Sclerosis, Philipps University Marburg, Marburg, Germany.
Tania KümpfelInstitute of Clinical Neuroimmunology, University Hospital, Ludwig-Maximilian-University Munich, Munich, Germany.
Friedemann PaulDepartment of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Sandra NischwitzMax Planck Institute of Psychiatry, Munich, Germany.
Hayrettin TumaniDepartment of Neurology, University of Ulm, Ulm, Germany.ORCID https://orcid.org/0000-0002-1647-6201
Uwe ZettlDepartment of Neurology, Neuroimmunological Section, University of Rostock, Rostock, Germany.
Bernhard HemmerDepartment of Neurology, Klinikum rechtsDer Isar, Technical University of Munich, Munich, Germany.ORCID https://orcid.org/0000-0001-5985-6784
Heinz WiendlDepartment of Neurology with Institute of Translational Neurology, Medical Faculty, University Hospital, Münster, Germany.ORCID https://orcid.org/0000-0003-4310-3432
Frauke ZippDepartment of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Ralf GoldDepartment of Neurology, St. Josef-Hospital Bochum, Ruhr-University Bochum, Bochum, Germany.ORCID https://orcid.org/0000-0002-7223-3052
St. Josef-Hospital · DEJohannes Gutenberg University Mainz · DETUM Klinikum · DEMax Delbrück Center · DEUniversity of Bern · CHHeidelberg University · DEHeinrich Heine University Düsseldorf · DELeipzig University · DELudwig-Maximilians-Universität München · DEMax Planck Institute of Psychiatry · DEMedizinische Hochschule Hannover · DEPhilipps University of Marburg · DEUniversität Hamburg · DEUniversität Ulm · DEUniversity Hospital Münster · DEUniversity of Augsburg · DEUniversity of Rostock · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Depression has a major impact on the disease burden of multiple sclerosis (MS). Analyses of overlapping MS and depression risk factors [smoking, vitamin D (25-OH-VD) and Epstein-Barr virus (EBV) infection] and sex, age, disease characteristics and neuroimaging features associated with depressive symptoms in early MS are scarce. Objectives: To assess an association of MS risk factors with depressive symptoms within the German NationMS cohort. Design: Cross-sectional analysis within a multicenter observational study. Methods: Baseline data of Results: Mean age was 34.3 years (95% confidence interval: 33.6-35.0). The female-to-male ratio was 2.3:1. At least minimal depressive symptoms (BDI-II > 8) were present in Conclusion: Depressive symptoms need to be assessed in early MS. Patients during relapse seem especially vulnerable to depressive symptoms. Contributing factors such as fatigue, vitamin D deficiency and smoking, could specifically be targeted in future interventions and should be investigated in prospective studies.

Indexed as

CISclinically isolated syndromecohort studydepressionMRIMSneuropsychological symptomsrelapsesexsmokingvitamin D

Identifiers

PMID37692259
PMCPMC10492471
OpenAlexW4386549191

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.